Epizyme Inc EPZM:NASDAQ

Last Price$0.45NASDAQ Previous Close - Last Trade as of 3:58PM ET 5/24/22

Today's Change-0.03(6.50%)
Bid (Size)$0.44 (5)
Ask (Size)$0.48 (22)
Day Low / High$0.44 - 0.48
Volume1.4 M
 

View Biotechnology IndustryPeer Comparison as of 05/24/2022

 

Epizyme Inc ( NASDAQ )

Price: $0.45
Change: -0.03 (6.50%)
Volume: 1.4 M
3:58PM ET 5/24/2022
 
 

Galectin Therapeutics Inc ( NASDAQ )

Price: $1.19
Change: -0.13 (9.85%)
Volume: 97.6 K
3:57PM ET 5/24/2022
 
 

Adverum Biotechnologies Inc ( NASDAQ )

Price: $0.84
Change: +0.02 (1.99%)
Volume: 545.5 K
3:58PM ET 5/24/2022
 
 

Homology Medicines Inc ( NASDAQ )

Price: $1.39
Change: -0.09 (6.08%)
Volume: 250.4 K
3:58PM ET 5/24/2022
 
 

Synlogic Inc ( NASDAQ )

Price: $1.12
Change: -0.09 (7.44%)
Volume: 94.4 K
3:58PM ET 5/24/2022
 

Read more news Recent News

--HC Wainwright Adjusts Epizyme Price Target to $8 From $10, Maintains Buy Rating
10:48AM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Epizyme to $7 From $9, Maintains Outperform Rating
3:17PM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (EPZM) EPIZYME Posts Q1 Revenue $8.7M
7:08AM ET 5/10/2022 MT Newswires

...

Epizyme Chief Medical and Development Officer Shefali Agarwal Resigns
5:18PM ET 4/06/2022 MT Newswires

Epizyme (EPZM) said Chief Medical and Development Officer Shefali Agarwal has resigned to "pursue other business opportunities." Following her...

Company Profile

Business DescriptionEpizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. View company web site for more details
Address400 Technology Square
Cambridge, Massachusetts 02139
Phone+1.617.229.5872
Number of Employees124
Recent SEC Filing05/24/20228-K
President, Chief Executive Officer, CFO & DirectorGrant C. Bogle
Chief Operating OfficerJerald Korn
Chief Scientific Officer & Executive VPJeffery L. Kutok
Secretary, Senior Vice President & General CounselJohn F. Weidenbruch

Company Highlights

Price Open$0.48
Previous Close$0.48
52 Week Range$0.44 - 9.86
Market Capitalization$74.7 M
Shares Outstanding164.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.20
Beta vs. S&P 500N/A
Revenue$21.7 M
Net Profit Margin-614.08%
Return on Equity-1,287.29%

Analyst Ratings as of 02/02/2022

Buy
3
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset